Gary Stetz Sells 12,500 Shares of Hillstream Biopharma (NASDAQ:CNTN) Stock

Hillstream Biopharma Inc. (NASDAQ:CNTN) Director Gary Stetz sold 12,500 shares of the company’s stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $3.47, for a total transaction of $43,375.00. Following the completion of the sale, the director owned 134,175 shares in the company, valued at approximately $465,587.25. This trade represents a 8.52% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Hillstream Biopharma Stock Down 1.8%

NASDAQ:CNTN traded down $0.06 during mid-day trading on Wednesday, reaching $3.23. The stock had a trading volume of 550,879 shares, compared to its average volume of 756,064. The stock has a market cap of $225.49 million, a P/E ratio of -2.81 and a beta of 1.44. Hillstream Biopharma Inc. has a 1-year low of $1.08 and a 1-year high of $9.08. The business has a 50 day simple moving average of $3.33.

Hillstream Biopharma (NASDAQ:CNTN) last announced its quarterly earnings data on Wednesday, May 13th. The company reported ($0.23) earnings per share (EPS) for the quarter.

Analyst Ratings Changes

Several equities analysts recently issued reports on the company. Wall Street Zen upgraded Hillstream Biopharma from a “sell” rating to a “hold” rating in a research note on Saturday, May 16th. Weiss Ratings lowered shares of Hillstream Biopharma from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, May 15th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, Hillstream Biopharma has a consensus rating of “Sell”.

Hillstream Biopharma Company Profile

Hillstream BioPharma, Inc, a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) for the treatment resistant cancers. The company’s product candidate is HSB-1216, an IMCD inducer targeting solid tumors. It also develops HSB-888, a dual Quatramer loaded IMCD inducer coupled with its anthracycline analogue for solid tumors; HSB-510, a targeted bifunctional inhibitory compound in Quatramer with single digit nanomolar; IC50 against PI3K-delta and HDAC6, which is also known to downregulate; c-myc, a cancer drug target; and HSB-114, an immunotherapeutic agent, which uses its Quatramer technology to deliver tumor necrosis factor-alpha gene into cancer cells.